MAPT and Alzheimer disease: The currently best validated CSF biomarkers, pTau and Aβ-42, with a reported sensitivity and specificity of around 90% for the diagnosis of AD, show at least some, if inconstant, correlations with cerebral tau and Aβ pathology [125, 130, 160, 161].